Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
9
×
life sciences
national blog main
boston blog main
san francisco blog main
biotech
boston top stories
national top stories
san francisco top stories
cancer
fda
national
raleigh-durham blog main
raleigh-durham top stories
roche
blueprint medicines
cancer drugs
europe blog main
new york blog main
new york top stories
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
third rock ventures
wisconsin blog main
wisconsin top stories
abbvie
amgen
avapritinib
boston
boulder/denver blog main
boulder/denver top stories
colorectal cancer
deals
deciphera pharmaceuticals
detroit blog main
What
cancer
9
×
drug
ipo
medicines
fda
research
approval
bio
blueprint
marketing
medicine
proteins
revolution
roundup
targets
abbvie’s
advanced
ahead
announced
arrival
award
biofourmis
biotech
black
blood
broader
bucks
cancer’s
candidate
celebrate
chance
chasing
clinic
companies
company
corner
currently
data
day
days
Language
unset
9
×
Current search:
cancer
×
unset
×
" clinical trials "
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug